BIOMAT Database Logo BIOMAT Database Logo

Dioxolane guanosine 5'-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses. 2003

Jerry L Jeffrey, and Joy Y Feng, and C C Richard Qi, and Karen S Anderson, and Phillip A Furman
Triangle Pharmaceuticals, Inc., a subsidiary of Gilead Sciences, Durham, North Carolina 27717, USA.

The frequency of human immunodeficiency virus, type 1 (HIV-1) mutations in response to antiviral therapy and resulting drug resistance is of major concern. Amdoxovir ((-)-beta-D-2,6-diaminopurine dioxolane), the prodrug of dioxolane guanosine (DXG), is currently in phase I/II clinical development for the treatment of HIV-1 infection. In vitro, HIV-1 mutants resistant to 3'-azido-3'-deoxythymidine (M41L/D67N/K70R/T215Y/K219Q) and (-)beta-L-2',3'-dideoxy-3'-thiacytidine (3TC) (M184V) remain sensitive to DXG. HIV-1 with the reverse transcriptase mutations K65R, L74V, and/or Q151M were less sensitive to DXG, whereas the mutation K103N re-sensitized the virus to the inhibitory effect of DXG. In order to understand these observations at the enzyme level, we investigated the inhibition of the HIV-1 reverse transcriptase-catalyzed viral DNA synthesis by dioxolane guanosine 5'-triphosphate (DXG-TP), 3'-azido-3'-deoxythymidine-TP, and 3TC-TP by using steady state kinetic analysis and the incorporation of DXG-5'-monophosphate by using pre-steady state kinetic analysis. This mechanistic study provided detailed information on the amdoxovir-related drug resistance at a molecular level. Overall, the enzymatic data correlated well with the antiviral data obtained from cell culture experiments and further supported the use of amdoxovir for the treatment of nucleoside reverse transcriptase inhibitor-experienced patients.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D003570 Cytidine Triphosphate Cytidine 5'-(tetrahydrogen triphosphate). A cytosine nucleotide containing three phosphate groups esterified to the sugar moiety. CTP,CRPPP,Magnesium CTP,Mg CTP,Triphosphate, Cytidine
D003843 Deoxycytidine Monophosphate Deoxycytidine (dihydrogen phosphate). A deoxycytosine nucleotide containing one phosphate group esterified to the deoxyribose moiety in the 2'-,3'- or 5- positions. DCMP,Deoxycytidylic Acid,Deoxycytidylic Acids,Acid, Deoxycytidylic,Acids, Deoxycytidylic,Monophosphate, Deoxycytidine
D003848 Deoxyguanine Nucleotides Guanine nucleotides which contain deoxyribose as the sugar moiety. Deoxyguanosine Phosphates,Nucleotides, Deoxyguanine,Phosphates, Deoxyguanosine
D004148 Dioxolanes
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D006151 Guanosine A purine nucleoside that has guanine linked by its N9 nitrogen to the C1 carbon of ribose. It is a component of ribonucleic acid and its nucleotides play important roles in metabolism. (From Dorland, 28th ed)
D006160 Guanosine Triphosphate Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety. GTP,Triphosphate, Guanosine
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities

Related Publications

Jerry L Jeffrey, and Joy Y Feng, and C C Richard Qi, and Karen S Anderson, and Phillip A Furman
Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase.
February 2008, The Journal of biological chemistry,
Jerry L Jeffrey, and Joy Y Feng, and C C Richard Qi, and Karen S Anderson, and Phillip A Furman
Pre-steady state kinetic analysis of cyclobutyl derivatives of 2'-deoxyadenosine 5'-triphosphate as inhibitors of HIV-1 reverse transcriptase.
June 2012, Bioorganic & medicinal chemistry letters,
Jerry L Jeffrey, and Joy Y Feng, and C C Richard Qi, and Karen S Anderson, and Phillip A Furman
HIV-1 reverse transcriptase mutants resistant to nonnucleoside reverse transcriptase inhibitors do not adversely affect DNA synthesis: pre-steady-state and steady-state kinetic studies.
August 2006, Journal of acquired immune deficiency syndromes (1999),
Jerry L Jeffrey, and Joy Y Feng, and C C Richard Qi, and Karen S Anderson, and Phillip A Furman
Steady-state kinetic studies with the polysulfonate U-9843, an HIV reverse transcriptase inhibitor.
January 1994, Experientia,
Jerry L Jeffrey, and Joy Y Feng, and C C Richard Qi, and Karen S Anderson, and Phillip A Furman
Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E.
March 1993, The Journal of biological chemistry,
Jerry L Jeffrey, and Joy Y Feng, and C C Richard Qi, and Karen S Anderson, and Phillip A Furman
Mechanistic studies to understand the inhibition of wild type and mutant HIV-1 reverse transcriptase by Carbovir-triphosphate.
January 2001, Nucleosides, nucleotides & nucleic acids,
Jerry L Jeffrey, and Joy Y Feng, and C C Richard Qi, and Karen S Anderson, and Phillip A Furman
Pre-steady state kinetic analysis of HIV-1 reverse transcriptase for non-canonical ribonucleoside triphosphate incorporation and DNA synthesis from ribonucleoside-containing DNA template.
March 2015, Antiviral research,
Jerry L Jeffrey, and Joy Y Feng, and C C Richard Qi, and Karen S Anderson, and Phillip A Furman
Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase.
February 1996, Protein expression and purification,
Jerry L Jeffrey, and Joy Y Feng, and C C Richard Qi, and Karen S Anderson, and Phillip A Furman
QSAR studies for diarylpyrimidines against HIV-1 reverse transcriptase wild-type and mutant strains.
February 2009, European journal of medicinal chemistry,
Jerry L Jeffrey, and Joy Y Feng, and C C Richard Qi, and Karen S Anderson, and Phillip A Furman
Evolution of inhibitor-resistant natural mutant forms of HIV-1 protease probed by pre-steady state kinetic analysis.
November 2017, Biochimie,
Copied contents to your clipboard!